Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KPL-914 (Arcalyst) Pilot Study in Recurrent Pericarditis
NCT03980522Phase 2Completed
- Sponsor
- Kiniksa Pharmaceuticals
- Start
- Jan 2018
- Primary completion
- May 2019
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, open-label trial of rilonacept in recurrent pericarditis (5 arms), sponsored by Kiniksa Pharmaceuticals. Primary endpoints: Pretreatment C-Reactive Protein Levels at Day 0, On-Treatment Change From Baseline Over Time in CRP Levels and 2 more. Started Jan 2018; status: completed.
02
Drugs
rilonacept
03
Conditions
recurrent pericarditis
Beyond the preview
Go deeper on NCT03980522.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03980522.